<DOC>
	<DOCNO>NCT02743013</DOCNO>
	<brief_summary>This clinical pharmacology study perform evaluate total systemic exposure lung availability CHF 5993 DPI pMDI without valved hold chamber , healthy volunteer .</brief_summary>
	<brief_title>Clinical Pharmacology Study Evaluate Total Systemic Exposure Lung Availability CHF 5993 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Subject 's write informed consent obtain prior study related procedure . 2 . Ability understand study procedure , risk involve , ability train use pMDI device correctly AIM™ ( Aerosol Inhalation Monitor ) Vitalograph® . 3 . Ability generate sufficient PIF ( least 40 L/min ) use InCheck device simulate NEXThaler® device . 4 . Male female Caucasian subject age 18 55 year inclusive . 5 . Body mass index ( BMI ) within range 18 30 kg/m2 inclusive . 6 . Nonsmokers exsmokers smoke &lt; 5 pack year ( packyears = number cigarette pack per day , time number year ) stop smoke &gt; 1 year prior screen . 7 . Good physical mental status , determine basis medical history general clinical examination , screen randomization . 8 . Lung function measurement within normal limit ( Normal value : FEV1/FVC &gt; 0.70 FEV1 &gt; 80 % predict ) . 9 . Female subject nonchildbearing potential ( WONCBP ) define physiologically incapable become pregnant ( i.e . postmenopausal permanently sterile ) female subject childbearing potential ( WOCBP ) fulfil one follow criterion : WOCBP fertile male partner : and/or partner childbearing potential must willing use double barrier contraceptive method include one highly effective birth control method one acceptable birth control method ( male female condom without spermicide and/or cap , diaphragm sponge spermicide ) , signature inform consent 3 month followup visit ; WOCBP nonfertile male partner : contraception require case . 1 . Blood donation ( equal 450 ml ) blood loss , less 8 week prior screen prior randomization . 2 . Abnormal haemoglobin level define &lt; 10.5 g/dl 3 . For female : pregnant lactate female subject , confirm positive serum test screen and/or urine test randomization . 4 . Positive HIV1 HIV2 serology . 5 . Positive result Hepatitis serology indicate acute chronic Hepatitis B Hepatitis C. 6 . Unsuitable vein repeat venipuncture . 7 . Documented history alcohol abuse within 12 month prior screen . 8 . Documented history drug abuse within 12 month prior screen , positive urine drug test perform screen and/or randomization . 9 . Subjects positive urine test cotinine screen and/or randomization . 10 . Clinically relevant abnormal laboratory value , suggest unknown disease require clinical investigation . 11 . Clinically relevant uncontrolled respiratory , cardiac , hepatic , renal , gastrointestinal , endocrine , metabolic , neurologic , psychiatric disorder may interfere successful completion protocol . 12 . Subjects medical diagnosis narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction opinion investigator would prevent use anticholinergic . 13 . Subjects history asthma , include childhood asthma . 14 . Known intolerance/ hypersensitivity excipients contain formulation use trial . 15 . Abnormal 12lead digitize Electrocardiogram ( 12lead ECG ) parameter ( i.e . : QRS &gt; 120 msec and/or PR &gt; 220 msec and/or HR &lt; 40 bpm and/or HR &gt; 110 bpm and/or QTcF &gt; 450 m male QTcF &gt; 470 m female , consider average triplicate ) 12lead ECG evaluate abnormal clinical significant investigator , screen . 16 . Abnormal Blood Pressure ( i.e . : Diastolic Blood Pressure &gt; 90 mmHg and/or Systolic Blood Pressure &gt; 140 mmHg , consider average triplicate ) screening . 17 . Participation another clinical trial investigation drug receive less 8 week prior screen . 18 . Subject take drug treatment , include prescribed OTC medicine well vitamin , homeopathic remedy etc , 14 day screen , exception : 1 . Occasional paracetamol ( maximum 2 g per day maximum 10 g per 14 day mild nonexcluding condition ) ; 2 . Hormonal contraceptive ; 3 . Hormonal replacement treatment postmenopausal woman . 19 . Subject take enzymeinducing drug , enzymeinhibiting drug , biologic drug drug know welldefined potential hepatotoxicity ( e.g . isoniazide , nimesulide , ketoconazole ) 3 month screen . 20 . Heavy caffeine drinker ( &gt; 5 caffeinated beverage e.g. , coffee , tea , cola per day ) . 21 . Subject low respiratory tract infection within 4 week prior screen prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>